Dew, I agree. I also feel that when more uses are researched for this type of application and positive medical outcomes are are documented, the general public(parents)will hop on board even if the costs remain high for a time.
Nice to see some productive conversation around here. I've been investing in CBAI for many months now and reading alot about this technology. Concerning the royalties I thought I had read sometime back that the only company who accepted to pay the royalties was CBAI instead of going to court...along with other similar companies using the patent.
And that the royalties had stopped once the court hearings were dismissed against similar companies for the patent. Are these fees going to return to CBAI in the event they should've stopped before 2010
All of the patents are scheduled to expire in 2010. Cord Partners is obligated under the Patent License Agreement to pay royalties to PharmaStem of 15% of all revenues generated by Cord Partners from the collection and storage of cord blood on and after January 1, 2004. Other than royalties, no amount is payable by Cord Partners to PharmaStem. All litigation between the parties was dismissed and all prior claims were released. As of 2008, Cord has ceased paying all royalties to Pharmastem. The patents have been declared void. This decision is currently under a final appeal. The company continues to accrue the fees on their books.
News 
Market Data 
Discover 
AI
